HEAL:LSE:LSE-iShares Healthcare Innovation UCITS ETF USD (Acc) (USD)

ETF | Others |

Last Closing

USD 7.62

Change

-0.06 (-0.75)%

Market Cap

USD 1.07B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

N/A

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

N/A

USD 292,109.19B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 592.18B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 592.18B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 331.07B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B

ETFs Containing HEAL:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.06% 33% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.06% 32% F 38% F
Trailing 12 Months  
Capital Gain -0.16% 18% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.16% 17% F 33% F
Trailing 5 Years  
Capital Gain 23.75% 43% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.75% 41% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 7.41% 62% D 66% D+
Dividend Return 7.41% 61% D- 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.02% 20% F 32% F
Risk Adjusted Return 25.55% 50% F 62% D
Market Capitalization 1.07B 81% B- 69% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.